Weekly Issue — 2025-08-17

For years, the simple story about GLP-1 receptor agonists went like this: they mimic a gut hormone, slow digestion, blunt appetite, and help the pancreas behave. That story was true, but incomplete. A 2025 review in the American Heart Journal Plus lays out how semaglutide is now being repositioned as a cardiometabolic drug, with benefits that show up in trials of people who do not have diabetes at all — including reductions in major adverse cardiovascular events, improvements in heart failure symptoms in the STEP-HFpEF trial, and measurable drops in inflammatory markers like C-reactive protein and TNF-α. The SELECT trial, also discussed in that review, found cardiovascular benefits in non-diabetic adults with obesity, hinting that something beyond weight loss is doing the work.

That "something beyond" is exactly what a German-led team set out to find. In a study published in the European Journal of Heart Failure, researchers took human ventricular heart tissue — from non-failing donors, from patients with aortic stenosis and a HFpEF-like profile, and from people with end-stage heart failure — and exposed it to semaglutide in the lab. The drug reduced abnormal late sodium currents, calmed leaky calcium handling inside heart cells, and improved contractility in the diseased tissue. When they blocked the GLP-1 receptor, the effect disappeared, which suggests the drug is talking directly to cardiomyocytes, not just helping indirectly through weight or glucose.

If you are reading this between night feeds, here is the honest translation. Cardiovascular disease is the long shadow behind most adult health worries — the thing your pediatrician's waiting-room posters quietly nod at when they mention "family heart history." For a long time, the only levers we had were the familiar ones: move more, eat better, sleep (ha), take a statin if your doctor says so. The new research suggests this drug class may add a different kind of lever, one that works at the level of heart muscle cells and chronic inflammation. That is genuinely new. It is also not a green light to ask for a prescription on the way home from daycare pickup.

The evidence so far is best described as moderate and converging. Multiple 2025 papers point in the same direction, but the strongest cardiovascular trials were done in specific populations — adults with obesity, with diabetes, or with heart failure with preserved ejection fraction — and the cell-level work, while elegant, is laboratory science, not a clinical recommendation.

Tirzepatide is the newer entrant — a dual agonist that hits both the GIP and GLP-1 receptors. In practice, that has translated to bigger A1c reductions and more weight loss than older single-receptor drugs. A 2025 retrospective study in Pharmacotherapy followed 66 patients with type 2 diabetes who switched from a GLP-1 agonist to tirzepatide while continuing insulin. Over six months, the median insulin dose dropped from 101 units to 71 units, a roughly 9% reduction, with patients starting at lower A1c levels needing the biggest cuts. The clinical takeaway from the authors: switching is not a casual swap, and insulin needs proactive adjustment to avoid hypoglycemia.

Tirzepatide also showed up in a more unexpected place this year. An Advanced Science paper reported that in mouse models of colon cancer — including a patient-derived xenograft — tirzepatide inhibited tumor cell proliferation, promoted apoptosis, and induced durable tumor regression, whether or not the mice were hyperglycemic. The proposed mechanism is metabolic: the drug appeared to throttle glucose uptake and destabilize HIF-1α, a master regulator that cancers lean on. This is genuinely preclinical work in animals. It is not, repeat not, evidence that anyone should take tirzepatide to prevent or treat cancer. But it is a clue worth following.

You do not need to memorize the trial names. What is useful is a simple frame: this drug class is graduating from a single-purpose tool (lower blood sugar, lower weight) into something more like a cardiometabolic therapy with effects on inflammation, on heart muscle biology, and possibly on tumor metabolism. Some of those effects are well-supported in human trials. Others are early signals from cells in dishes and mice in labs. Holding both in mind at once is the grown-up move.

The practical version, for someone in the trenches of toddler dinners and sleep regressions: if you or your partner has been told you are at elevated cardiometabolic risk — high A1c, obesity, a heart failure diagnosis, a family pattern that worries your clinician — this is a reasonable conversation to have at your next appointment. Not a demand for a prescription. A conversation about whether the newer evidence changes the math for you specifically. And if you are already on one of these medications, the Pharmacotherapy data is a good reminder to talk to whoever manages your insulin before any switch.

The thing about being a parent of small kids is that the long view feels theoretical. The heart you are protecting is the one that will, in theory, still be working when your toddler is borrowing the car. The research moving through journals this year does not change the basics — sleep when you can, move when you can, eat the vegetables your kid rejected — but it does suggest the medical toolbox for cardiometabolic health is genuinely expanding. That is a hopeful story, told carefully. Carefully is the only way to tell it right now.

The short version: a wave of new papers suggests these drugs behave less like a single-purpose appetite tool and more like a multi-organ protective therapy. A 2025 review in Peptides lays out the case directly, describing incretin-based medicines as agents that lower glucose and weight, yes, but also confer benefits against cardiovascular and renal disease that go beyond what those two changes alone would predict — with emerging signals for fatty liver disease, chronic inflammation, sleep apnea, and possibly bone and cognitive health. The authors also catalogue a growing pharmacy of next-generation molecules — dual and triple agonists, peptide-antibody hybrids, oral versions — that are pushing the category well past semaglutide and tirzepatide. You can read the full taxonomy in the review itself.

That is the optimistic frame. Now the honest one: most of this is moderate-strength evidence. Some of it is preclinical. Some is retrospective. None of it justifies treating a GLP-1 like a cure-all, and none of it should be acted on without a clinician who actually knows your chart.

Cardiac remodeling — the gradual thickening and scarring of heart muscle under chronic strain — is the kind of slow-motion problem that ends careers in cardiology. So it was notable when a 2025 paper in the Journal of Cellular and Molecular Medicine reported that danuglipron, a novel oral GLP-1 receptor agonist, meaningfully reduced pressure-overload-induced hypertrophy and fibrosis in mice. The mechanism is the interesting part: the drug appears to work through AMPK phosphorylation and a bump in HSP70, easing apoptosis and supporting autophagy. When the researchers knocked out AMPKα2, the cardioprotection vanished — strong evidence the pathway is real, not coincidence. The full study is here.

Caveat the size of a barn: this is a mouse model. Danuglipron is not approved, and oral GLP-1 development has had a bumpy road. What this paper offers is a plausible biological story for why GLP-1 receptor activation might do something useful for stressed hearts — a hypothesis worth chasing, not a prescription.

This is where the evidence gets sturdier — and more personally relevant for anyone navigating diabetes and weight in midlife. A retrospective cohort study published in The Lancet Diabetes & Endocrinology in 2025 looked at U.S. kidney transplant recipients with type 2 diabetes — a group routinely excluded from the big GLP-1 trials because they are too complicated: longer diabetes duration, more end-organ damage, more cardiovascular risk, more medications. Using a national registry linked to Medicare claims, the researchers identified more than 44,000 first-time kidney transplant recipients and examined what happened when post-transplant patients started a GLP-1 receptor agonist. Their framing is cautious but the question is exactly the right one: do the benefits seen in healthier trial populations carry over to the patients who arguably need them most? The full paper is the place to dig in.

Dialysis patients have been similarly invisible in pivotal trials. A 2025 letter in Cardiovascular Diabetology highlights that the 2022 KDIGO guideline already endorses GLP-1 receptor agonists for patients with chronic kidney disease and type 2 diabetes who have not hit glycemic targets on metformin and an SGLT-2 inhibitor — and signals potential benefit even in dialysis-requiring acute kidney disease, possibly via the drug class's pleiotropic effects. The authors are appropriately careful: pharmacokinetics and dialysis dose were not fully accounted for, and they flag this as a real limitation. Their commentary is worth reading in full. Translation for the rest of us: promising direction, incomplete map.

Here is the entry on the list that made every editor in our newsroom do a double take. A 2025 prospective cohort study in the Journal of Orthopaedic Surgery and Research followed more than 2,000 adults with chronic ankle instability — the chronic sprain-and-roll problem that haunts people who once played sports or who simply carry extra load on imperfect joints — across three medical centers for at least two years. Seventy-one of those patients received semaglutide during the study period, prescribed for diabetes or weight loss. After adjusting for baseline differences, the semaglutide group showed a 16.3-point improvement on the FAAM sports subscale and 9.3 points on the activities-of-daily-living subscale, with consistent gains across Foot and Ankle Outcome Score subscales and the Cumberland Ankle Instability Tool. The authors note the effect was mediated, at least in part, by weight loss. The full study is here.

Is this evidence that GLP-1s are a treatment for bad ankles? No. It is evidence that taking meaningful load off joints, in a population that was unstable to begin with, may translate into measurably better function and fewer sprains. Which, if you have ever rolled your ankle stepping off a curb at 47, is its own small revolution.

If you are a woman somewhere in the perimenopausal sprawl, weighing whether a GLP-1 belongs in your life, the new research does not hand you an answer. It does change the shape of the conversation. The question is no longer just "will this help me lose weight?" It is also "what else might this be doing — for better, and worth monitoring — in a body that is also juggling shifting hormones, blood pressure, cholesterol, and joints that have opinions?" That is a conversation for an actual clinician with your labs in front of them, not for a magazine. But it is a more interesting conversation than it was a year ago.

The hype cycle will keep doing what hype cycles do. The science, meanwhile, is getting more careful, more curious, and — refreshingly — more honest about who has been left out of the trials. That is the part to watch.

Bariatric surgery is one of the most effective interventions in modern metabolic medicine — and also one of the most quietly frustrating. Weight regain is common, sometimes years later, and until recently the playbook for what to do about it has been thin. A Swiss retrospective study of 40 post-bariatric patients, published in BMC Endocrine Disorders, asked a practical question: can a GLP-1 actually rescue the regain?

The answer, at 12 months, was a striking yes. Patients started a GLP-1 a median of roughly six years after surgery, after regaining about 15% of their body weight. After a year on either liraglutide 3.0 mg daily or semaglutide 1.0 mg weekly, they had lost a median of 10.5 kg — essentially all of the weight they had regained, with semaglutide outperforming liraglutide on BMI reduction. It's a single center and a small cohort, so don't read it as the last word. Read it as the first solid real-world signal that the regain phase has a serious pharmacologic option.

If you've felt like the headline numbers from the GLP-1 trials don't quite match the stories you hear from friends, you're not imagining it. A new narrative review in Diabetes, Obesity & Metabolism pulled together the contemporary real-world evidence on liraglutide, semaglutide and tirzepatide and found a consistent pattern: weight loss in clinical practice tends to be lower than in the randomized trials, with discontinuation rates of 20%–50% in the first year and many patients on doses well below those studied.

The same review offers a measured read on safety: gastrointestinal side effects are common, as expected, but observational data so far show no clear signal for pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm in obesity or type 2 diabetes populations. The authors flag eye disease and other rare outcomes as still needing more evidence — which sets up the next finding.

The neuroprotection story is the most exciting thread in the new data — and the one most easily overstated. A network meta-analysis in BMC Medicine pooled randomized trials of GLP-1 receptor agonists and SGLT2 inhibitors and looked at the incidence of seven neurodegenerative diseases, from Parkinson's and Alzheimer's to ALS. The authors framed it as a pharmacodynamics-based evaluation of prophylactic benefit across major neurodegenerative diseases, suggesting these drugs may carry preventive potential beyond their metabolic effects.

Here's the careful read. Almost none of the included trials were designed to test prevention of dementia or Parkinson's — those outcomes were captured as adverse events or secondary signals. A network meta-analysis can surface a trend that warrants dedicated studies; it can't substitute for them. So: a real and biologically plausible signal, in line with years of preclinical neuroprotection work, and absolutely worth watching. Just not, yet, a reason to start a GLP-1 to protect your brain.

The most discussed safety story of the spring came from a pharmacovigilance analysis, also in BMC Medicine, that mined the FDA Adverse Event Reporting System (FAERS) for vision-impairment reports linked to semaglutide. Compared with other GLP-1 receptor agonists, semaglutide had a reporting odds ratio of 1.95 for vision impairment (95% CI 1.75–2.17), with higher ratios still versus DPP-4 inhibitors, SGLT2 inhibitors, metformin, and orlistat. Topiramate was the only comparator that out-reported it.

What FAERS can and can't do matters here. It's a passive reporting system, vulnerable to media-driven reporting waves and unable on its own to prove that a drug caused an event. What it does well is raise hypotheses worth testing. The authors are explicit that their findings warrant further investigation and vigilant post-marketing surveillance, and the real-world review echoed that eye outcomes need more evidence. If you're on semaglutide and notice changes in your vision, that's a call to your prescriber, not a reason to panic.

Read together, these four papers tell a coherent story about where GLP-1s are heading. They are maturing from a single-outcome weight drug into a broader metabolic-neuro toolkit, with a credible new use case in post-bariatric regain, a tantalizing brain-protection hypothesis, and a vision-safety question that deserves serious follow-up rather than dismissal or alarm. The drugs are not miracles, and they are not menaces. They are, increasingly, a long-term relationship — one in which the right questions, the right monitoring, and the right prescriber matter more than any single headline.